T1	Premise 742 887	The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods.
T2	Premise 888 1006	Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period.
T3	Premise 1007 1225	At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%.
T4	Premise 1226 1575	At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (< or = 3.2) and DAS28 (C-reactive protein)-defined remission (< 2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6).
T5	Premise 1576 1721	Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.
T6	Premise 1722 1793	No unique safety observations were reported during open-label exposure.
T7	Premise 1794 2026	Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.
